[Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer].
OBJECTIVE
To evaluate the effect and toxicity of arsenic trioxide (As2O3) in treating primary liver and gallbladder cancer.


METHODS
Twenty-nine advanced primary liver cancer and 4 gallbladder cancer patients were treated with As2O3 injection only, 15 mg i.v. qd for 14-21 days and was repeated after 2 weeks.


RESULTS
The overall response rate was 15.2%, 13.8% in primary liver cancer (PR 4, NC 21 and PD 4). It was 25.0% in gallbladder cancer (CR 1, NC 2, PD 1). The major side reactions were mild bone marrow suppression and hepatic functional damage.


CONCLUSIONS
As2O3 injection is effective in treating primary liver and gallbladder cancer with mild side reactions. It is worth studying in the future.
Qian
J
J
Oncology Center, 81 Hospital, PLA, Nanjing 210002, China.
Qin
S
S
He
Z
Z
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005706:Gallbladder Neoplasms / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide